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The cephalosporin nucleus has proved to be tremen- 
dously amenable to modification, allowing more 
derivatives to be developed for clinical use than with 
any other antibiotic class. Different properties arise from 
modification, mainly at C3 for pharmacologic changes 
and C7 for antibacterial properties. This has allowed the 
development of four generations of cephalosporins, 
notable for their stability to p-lactamase enzymes 
but which are innately less active than corresponding 
penicillinases (Table 1). The third-generation cephalo- 
sporins (3GCs) were developed in the 1980s to combat 
the increasing problems of multiresistant, Gram- 
negative, hospital-aquired infections, particularly those 
due to the inducible Enterobacteriaceae. Initially, 
virtually all isolates were susceptible to these agents, 
although it soon became evident that resistance 
developed commonly during treatment with these 
drugs [l] (Table 2 ) .  Originally it was thought that this 
resistance was due to ‘trapping’ of stable drug by 
binding to chromosomal enzymes in the periplasmic 
space. In fact, the rate of hydrolysis of 3GCs by these 
Amber class 1 p-lactamases has now been shown to be 
fast enough to explain resistance when combined with 
the relatively slow penetration of these agents through 
the Gram-negative cell wall 121. 
The natural function of p-lactamases is thought to 
be primarily in the recycling of the cell wall during 
normal growth. Resistance to 3GCs by p-lactamase 
production occurs through three main routes. First, it 
can arise on exposure to an inducing agent, often an 
antibiotic such as a 3GC, although usually the rate of 
Corresponding author and reprint requests: 
I .  M. Gould, Department of Medical Microbiology, Aberdeen 
Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK 
Tel: +44 1224 840688 Fax: +44 1224 840632 
E-mail: I.M.Gould@abn.ac.uk 
Table 1 Development of the p-lactams: exaniples of shared 
active principles between different classes of p-lactams 
Cephalosporins Penicillin 
Cefoperazone 
Ceftazidime 
Cefoxitin 
Cephalexin 
Piperacillin 
Aztreonam 
Temocillin 
Ampicillin 
bacterial kill before induction of enzyme is enough to 
ensure clinical success. Second, and most clinically 
important, is the selection of derepressed mutants, 
stably producing high levels of class 1 enzyme. This 
seems to happen with a high frequency (around 
in clinical infection [3] and is responsible for some 
clinical and bacteriologic failures. Many institutions 
now have between 30% and 60% of isolates of 
Enterobacter spp. stably derepressed and showing outright 
resistance to 3GCs on susceptibility testing [4]. 
The third p-lactamase resistance mechanism to 
3GC among Gram-negative bacteria, which has only 
really become apparent in the last few years, is 
expanded-spectrum P-lactamase (ESBL) production. 
There are now over 40 ESBLs described [5]. Their 
prevalence is unknown, as most laboratories, at least 
in the UK, do not look for them routinely. While 
resistance to some 3GCs can be absolute, depending on 
enzyme and antibiotic, many strains carrying these 
enzymes appear susceptible on breakpoint or zone of 
inhibition. There is no definitive guide, and suscepti- 
bility also probably depends on such things as gene copy 
number, permeability and host species. ESBLs are 
mainly derivatives of the ubiquitous TEMl/2 and 
SHV-1 plasmid-mediated enzymes. The best way to 
detect them in a diagnostic laboratory is by the Jarlier 
test 161, which can be easily incorporated into routine 
disk suceptibility testing by approximating a p-lacta- 
mase inhibitor-containing disk with a 3GC disk. A 
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Table 2 Rates of emergence of resistance in patients infected with inducible Enterobacteriaceae [I] 
Drug Organism 
Number of 
Total number patients with Frequency of clinical 
of patients emerging resistance failure or relapse 
Ceftriaxone Several 
Moxalactam Serratia marcescens 
Moxalactam Several 
Several Entero6acfev species 
Several Several 
29 
10 
10 
9 
44 
recent survey suggested the prevalence of ESBLs among 
Klebsiella in European intensive care units (ICUs) was 
approximately 30% [7].  
Are the 4GCs the answer to these increasingly 
common resistance problems? The answer is a qualified 
yes. The great majority of stably derepressed mutants or 
ESBL producers will be susceptible to 4GCs in standard 
in vitro tests, but MICs are generally raised when 
compared with similar strains with inducible class 1 
enzymes or non-ESBL producers [S] (Tables 3, 4 and 
5). This appears to lead to some clinical failures, 
particularly in high-inoculum infections. 
Table 3 Comparative in vitro activity against clinical 
isolates of Edwichia coli and Klebsiella pneumoniae that 
produce ESBLs [S] 
~ ~ ~~ ~~ 
No of 
strains tested Antibiotic MIC range M I G O  %S" 
26 Cefepime 
Ceftazidime 
Cefotaxime 
18 Ceipirome 
Ceftazidime 
Cefotaxime 
33 Cefoselis 
Ceftazidime 
Cefotaxime 
0.25-64.0 32.0 
4.0 to >64.0 >64 
2.0 to >64.0 >64 
0.25 to >64.0 >64.0 
4.0 to 264.0 >64.0 
8.0-64.0 >64.0 
0.25-64.0 264.0 
4.0-64.0 >64.0 
0.25-64.0 >64.0 
77 
12 
19 
56 
6 
11 
63 
9 
36 
" S  =susceptible. 
The 4GCs are very similar to 3GCs, containing an 
aminothiazolyl group at C7. The main difference is a 
quaternary ammonium group at C3. Ceftazidime also 
has this structure but, because of its dianionic overall 
charge, does not penetrate the Gram-negative cell wall 
as quickly as 4GCs. In general, the 4GCs retain the 
antipseudomonal activity of cefiazidime and the anti- 
Enterobacteriaceae activity of cefotaxime while having 
improved anti-Gram-positive activity. 
Their pharmacokinetic properties are similar to 
those of most 3GCs. A twice daily dosing regimen of 
2 g should be adequate for moderately severe infections 
where a breakpoint of 4 mg/L is used, with T > MIC 
being maintained for approximately 50% of the dosing 
interval [9]. For more serious infections, they will need 
to be given 8-hourly. Penetration of the Gram-negative 
cell wall is as rapid as that of imipenem [lo], although 
they seem to be as susceptible as 3GCs to efflux 
mechanisms (unlike imipenem). Binding to penicillin- 
binding proteins (PBPs) shows some interesting varia- 
tions among the compounds [ll] (Table 6). Cefepime, 
with its much greater affinity for PBP2, should give 
more rapid kill and less inoculum effect due to less 
filament formation [ 121. Reduced endotoxin release 
and a postantibiotic effect (PAE) against Gram-negatives 
may be other benefits of this PBP binding profde [12]. 
Inoculum effects are almost certainly important 
in many infections where 4GCs will be used, e.g. 
ventilator-associated pneumonia, meningitis and intra- 
Table 4 Influence of depressed chromosomal and TEM3 p-lactamases on p-lactam activity [2] 
MIC (mg/L) 
Bacterium P-Lactamase Cefpirome Cefepime Cefaclidine Cefotaxime 
~ ~~ 
Enterobacter cloacae Inducible 0.05 0.05 0.1 
Constitutive 0.5 0.5 20 
Pseudomonas aemginosa Inducible 16 1 0.25 16 
Constitutive 4 0.25 256 
Esclzericlzia coli Background 0.13 0.13 0.13 0.03 
TEM3 1 1 4 32 
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Table 5 In vitro activity of third- and fourth-generation cephalosporins against Escherichia coli C600 producing ESBLs [S] 
0-Lactamase CAZ CFTX Cefaclidine Cefepime Cefpirome Cefoselis 
TEM-5 128 4.0 4.0 2.0 4.0 4.0 
TEM-6 128 1 .0 8.0 4.0 4.0 4.0 
TEM-I 0 1 1 2 8  2.0 2.0 2.0 2.0 
TEM-12 16 0.25 2.0 4.0 1 .o 
SHV-3 32 64 16 16 32 8.0 
SHV-2 32 64 32 16 32 32 
SHV-4 128 128 32 32 32 16.0 
SHV-5 128 64 8.0 16 16 16 
Table 6 Competition of cephalosporins for high-molecular 
weight PBPs of Escherichia coli rl11 
~ ~~ 
1% for PBP (mg/L) 
MIC 
Antibiotic 1A 1B 2 3 (1ndL) 
~~~ ~ 
Cefotaxime 0.05 0.7 5 <0.05 0.08 
Ceftriaxone 0.17 1 0.34 0.4 0.125 
Ceftazidinie 0.9 3.4 240 0.06 0.2 
Cefpirome 1.4 7 0.03 0.02 
Cefepime 1.5 0.25 0.03 0.01 
Cefachdine >2.5 >25 0.5 0.1 
abdominal infections, where bacterial density is 
frequently 107-10"' CFU/mL [13]. The MICs of 
filament-forming cephalosporins can be 100-1000 
times the in vitro MIC (assessed at 5 ~ 1 0 ~  CFU/mL). 
In vitro, 4GCs active against stably derepressed 
mutants may select for a second mutation, this time in 
the Rob-gene, leading to a decrease in porins, with 
consequent reduced permeability of 4GCs [14]. This 
mutation may also affect carbapenem permeability. 
This second mutation is probably most unlikely to 
occur on treatment of inducible organisms with either 
3GCs or 4GCs, but once selection of P-lactamase 
hyperproducing mutants (resistant to 3GCs) has occur- 
red, then treatment with 4GCs is likely to be 
problematic, with selection of a permeability mutant 
[15]. I t  is probably unwise to use 4GCs in this setting 
of difficult infection with stably derepressed mutants, 
unless used in combination with another drug. How- 
ever, this is a luxury that may not always be available, 
in which case a close watch should be kept for selection 
of the second-step mutation. 
At present, 4GCs can be used for treatment of 
infection with many ESBL producers, although, unless 
combined with a P-lactamase inhibitor, treatment failure 
may be a problem, depending on the specific enzyme 
involved and the inoculum of the infecting organism. 
High doses of 4GCs should be used in this situation. 
4GCs are more active against TEM ESBL producers 
than against those producing SHV ESBLs (Table 5) [ 8 ] .  
The clinical indications for 4GCs are potentially 
quite wide. Many randomized clinical trials show equal 
efficacy to comparators for community and nosocomial 
pneumonia, intra-abdominal infections, serious urinary 
tract infections and skin and soft tissue infections 
[16-201. Prelinlinary data also suggest good efficacy in 
meningitis [21]. Where cefepime offers better activity 
against Gram-negatives, cefpirome probably has slightly 
better efficacy against Gram-positives and may be an 
improvement on cefotaxime for methicillin-sensitive 
Staphylococcus aureus and penicillin-resistant pneumo- 
cocci [13,22]. The pharmacokinetics of 4GCs do  not 
appear to be affected by probenecid. 
Because of different (dissociated) susceptibilities to 
the various mechanisms of 0-lactamase resistance, the 
4GCs offer more ammunition in our battle against 
multi-resistance. Although these are early days, they do 
not seem to be affected by porin D2 loss in Pseudornonas 
aeruginosa as much as the carbapenems, they retain 
reasonable activity against Stenotrophonzonas unaltopldia, 
they are innately more active against most Gran- 
negatives than piperacillin-tazobactam, particularly 
against the inducible Enterobacteriacea, and they do 
not seem to lead to such rapid selection of resistant 
mutants in I? arruginosa and other Gram-negatives as the 
4-fluoroquinolones. Over the years, cephalosporins have 
gained an unenviable reputation for creating resistance 
problems such as the inducible chromosomal enzymes, 
ESBLs, and selecting for MRSA, Clortridium d f f i f f r  and 
enterococci [23]. While this is entirely explicable by 
their wide use and spectrum of action, within the 
proposed areas of use of cefepime, these problems 
should not be too great. 
Some intriguing studies are appearing, suggesting 
some unexpected benefits of cefepime, including 
improved efficacy (combined with metronidazole) 
compared with low-dose imipenem in serious intra- 
abdominal infections [24] and improved efficacy 
compared with ceftazidime (both combined with 
amikacin) in the treatment of nosocomial pneumonia 
[25]. These studies confirm the in vitro [26] and animal 
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model studies [27] showing improved penetration in a 
permeability-deficient mutant with better outcome 
than imipenem in a mouse model and, in mouse and 
rat models, similar efficacy to imipenem against TEM- 
3- and TEM-26-producing coliforms [28,29]. 
These studies suggest that the gap between cephalo- 
sporins and carbapenems is being closed with the 
development of the 4GCs. It also seems (from 
preliminary data) that where cefepime is substituted for 
3GCs on a formularly, then there is reversal of the high 
levels of resistance to the 3GCs among the inducible 
Enterobacteriaceae [30], probably because there is no 
survival value of stably derepressed mutants, which are 
efficiently killed by cefepime. There may also be 
reduced prevalence of the double mutation perme- 
ability mutants, resistant to 4GCs and often also to 
aminoglycosides and fluoroquinolones [31]. 
These data come from purely observational studies, 
however, where other factors are not controlled for, 
e.g. variable fluroquinolone use and infection control 
procedures, so more work needs to be done in thls area. 
If this exciting development is confirmed, it points the 
way forward for a clear policy in the use of these agents, 
either as an outright replacement for 3GCs or as 
another class of drug to be included along with 3GCs, 
carbapenems and broad-spectrum penicillins f a p- 
lactamase inhibitor in rotational cycles to prevent the 
emergence of resistance [32]. The ability of the 
clinician to add a p-iactamase inhibitor of his choice to 
a chosen cephalosporin would provide another very 
effective new series of drugs for treatment of serious 
sepsis, and we look forward to this and other develop- 
ments to combat the march of ESBL and chromosomal 
hyperproducers, now becoming more prevalent in 
other Enterobacteriaceae such as Klebsiella [33]. 
The 4GCs represent a timely advance in the 
treatment of serious, multiresistant infections and can 
confidently be used as alternatives to the new fluro- 
quinolones, antipseudomonal penicillins, 3GCs and 
carbapenems. 
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